“These results are really exciting. This could be a new front in the fight against MS.”
Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.
The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal.
The discovery could lead to an entirely new way to treat multiple sclerosis, which affects more than 2.3 million people worldwide.
Multiple sclerosis occurs when the body’s immune system attacks the myelin, or the protective sheath, surrounding nerve fibers of the central nervous system. Some underlying nerve fibers are destroyed. Resulting symptoms can include blurred vision and blindness, loss of balance, slurred speech, tremors, numbness and problems with memory and concentration.
The antioxidant research was published in the December edition of Biochimica et Biophysica Acta Molecular Basis of Disease. The research team was led by P. Hemachandra Reddy, Ph.D., an associate scientist in the Division of Neuroscience at OHSU’s Oregon National Primate Research Center.
To conduct their study, the researchers induced mice to contract a disease called experimental autoimmune encephalomyelitis, or EAE, which is very similar to MS in humans. They separated mice into four groups: a group with EAE only; a group that was given the EAE, then treated with the MitoQ; a third group that was given the MitoQ first, then given the EAE; and a fourth “control” group of mice without EAE and without any other treatment.
After 14 days, the EAE mice that had been treated with the MitoQ exhibited reduced inflammatory markers and increased neuronal activity in the spinal cord — an affected brain region in MS — that showed their EAE symptoms were being improved by the treatment. The mice also showed reduced loss of axons, or nerve fibers and reduced neurological disabilities associated with the EAE. The mice that had been pre-treated with the MitoQ showed the least problems. The mice that had been treated with MitoQ after EAE also showed many fewer problems than mice who were just induced to get the EAE and then given no treatment.
“The MitoQ also significantly reduced inflammation of the neurons and reduced demyelination,” Reddy said. “These results are really exciting. This could be a new front in the fight against MS.”
Even if the treatment continues to show promise, testing in humans would be years away. The next steps for Reddy’s team will be to understand the mechanisms of MitoQ neuroprotection in different regions of the brain, and how MitoQ protects mitochondria within the brain cells of the EAE mice. Mitochondria, components within all human cells, convert energy into forms that are usable by the cell.
There is a built-in advantage with MitoQ. Unlike many new drugs, MitoQ has been tested for safety in numerous clinical trails with humans. Since its development in the late 1990s, researchers have tested MitoQ’s ability to decrease oxidative damage in mitochondria.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- 'It is exciting': Multiple sclerosis vaccine could be byproduct of COVID-19 technologyon March 3, 2021 at 8:50 am
The breakthrough technology deployed to vaccinate against COVID-19 also has led to a promising new approach to preventing the progression of multiple sclerosis. That's an especially welcome ...
- Multiple Sclerosis Treatment Market Size Is Projected to Grow at 3.5% CAGR By 2023 | Share Analysis, Future Trends and SWOT Analysison March 3, 2021 at 12:52 am
Multiple Sclerosis Treatment Market Size, Trends and Growth Insights By Route of Administration (Injectable, Oral), Drug Type (Immunomodulators, ...
- Could rising temperatures send more people with multiple sclerosis to the hospital?on March 2, 2021 at 1:01 pm
As average temperatures around the globe climb, a preliminary study has found people with multiple sclerosis (MS) may expect worsening symptoms, enough to send them to the hospital more often. The ...
- Multiple Sclerosis Society holding virtual fundraising walkon March 2, 2021 at 6:00 am
Prevalence of MS is three times higher among women than men and an estimated 1 million Americans are living with the disease.
- The Multiple Sclerosis Association of America (MSAA) Focuses on Improving Mental Health and Wellness in Honor of MS Awareness Monthon March 1, 2021 at 9:02 am
The Multiple Sclerosis Association of America (MSAA) recognizes March as Multiple Sclerosis (MS) Awareness Month. MSAA is proud to announce the 2021 awareness campaign theme on Improving Mental Health ...
- Opioid Use Common for Pain in Multiple Sclerosison February 28, 2021 at 4:00 pm
A study shows that 20% of MS patients report prescription opioid use. The researchers urge development of more nonpharmacologic programs.
- Multiple Sclerosis and Depression: Are Links Causal?on February 28, 2021 at 12:13 pm
Relationships between multiple sclerosis (MS) and depression did not appear to be causal, a Mendelian randomization study suggested. Genetic liability to major depressive disorder had no effect on the ...
- Toll-like receptor-9 stimulated plasmacytoid dendritic cell precursors suppress autoimmune neuroinflammation in a murine model of multiple sclerosison February 26, 2021 at 3:07 am
We herein demonstrate that in vivo or in vitro activation within the BM via Toll-like receptor-9 generates a population of plasmacytoid dendritic cell (pDC) precursors (CpG-pre-pDCs) that, unlike pDC ...
- Multiple Sclerosis Therapies Market to Grow with a High CAGR- Global Industry Analysis, Key Manufacturers, Trends, Size, and Forecastson February 24, 2021 at 11:14 pm
Global Size, Share Report,Market Trends, Industry Forecast, Growth, Trends Analysis, Keyplayers & Regional Analysis (Latin America, North America, Asia Pacific, Europe, Middle East) "Global Multiple ...
- Pediatric-onset multiple sclerosis tied to lasting social consequenceson February 24, 2021 at 9:40 am
(HealthDay)—Pediatric-onset multiple sclerosis (PoMS) is associated with less educational achievement, lower earnings, and greater use of disability benefits throughout the working-age life span, ...
via Bing News